Search clinical trials for: FiAsp

Total 41 results

Medical University of Warsaw

Not yet recruiting

Does the Use of Fiasp vs. Asp Lead to the Prolonged TIR in Children With Type 1 Diabetes?

Diabetes Mellitus, Type 1 | Diabetes type1
University Hospital, Strasbourg, France

Recruiting

Effect of Postprandial Insulin Administration of Faster-acting Insulin Analogue Versus Pre-prandial Administration of Acting-insulin Analogue in Cystic Fibrosis Related Diabetes (MIRE)

Cystic Fibrosis-related Diabetes

France
Medtronic Diabetes

Active, not recruiting

Evaluation of the MiniMed™ 780G System in Type 1 Adult and Pediatric Subjects Utilizing Insulin Fiasp®

Type 1 Diabetes

United States, Canada, Australia
Novo Nordisk A/S

Enrolling by invitation

A Research Study Looking at How the Use of NovoPen® 6 for Treatment With Tresiba® & Fiasp® Affects the Blood Sugar Level in Patients With Type 1 Diabetes as Part of Local Clinical Practice (CONNECT 1)

Diabetes Mellitus, Type 1

Belgium, France, Denmark, Sweden
Novo Nordisk A/S

Completed

An Indian Post Marketing Study of Mealtime Insulin, Fiasp®, to Evaluate Its Safety and Effectiveness in Patients With Diabetes Mellitus in Routine Clinical Practice

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1

India
Boston Medical Center
Novo Nordisk A/S

Completed

Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus (In-FI)

Type 2 Diabetes Treated With Insulin

United States
Mannkind Corporation
Jaeb Center for Health Research

Active, not recruiting

Afrezza® INHALE-1 Study in Pediatrics (INHALE-1)

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1

United States
Jaeb Center for Health Research
Boston University; Massachusetts General Hospital; National Institute of Diabetes... and other collaborators

Completed

The Insulin-Only Bionic Pancreas Pivotal Trial

Diabetes Mellitus | Diabetes Mellitus, Type 1 | Type 1 Diabetes

United States
McGill University Health Centre/Research Institute...
Juvenile Diabetes Research Foundation

Completed

A Fully-closed Loop, Pramlintide and Insulin, Artificial Pancreas Clinical Trial for Adults With Type 1 Diabetes (FCL)

Type 1 Diabetes

Canada
Institut de Recherches Cliniques de Montreal

Completed

Comparison of FiAsp and Aspart During Postprandial Exercise in Adults With Type 1 Diabetes

Type 1 Diabetes Mellitus

Canada
Rigshospitalet, Denmark

Completed

Insulin Fiasp vs. Insulin Novorapid During Pregnancy and Laction in Women With Pre-existing Diabetes

Diabetes Mellitus | Pregnancy Complications

Denmark
McGill University
Juvenile Diabetes Research Foundation

Completed

Alleviating Carbohydrate Counting for Patients With Type 1 Diabetes Using a Novel Insulin-plus-pramlintide Artificial Pancreas

Type 1 Diabetes | Type 1 Diabetes Mellitus | Hyperglycemia, Postprandial

Canada
Arecor Limited

Completed

AT247, NovoLog® and Fiasp® Administered Via Continuous Subcutaneous Infusion in Glucose Clamp Study

Diabetes Mellitus, Type 1

United States
Manchester University NHS Foundation Trust
Novo Nordisk A/S

Completed

Comparison of Day and Night Closed-loop With Faster-acting Insulin Aspart With Insulin Aspart (AP-MFT-01)

Diabetes Mellitus, Type 1

United Kingdom
Steno Diabetes Center Copenhagen
University of Copenhagen; Technical University of Denmark; Danish Diabetes Academy

Completed

Dual-hormone Closed-loop Glucose Control in Type 1 Diabetes (DHCL2019)

Hypoglycemia | Type 1 Diabetes

Denmark
Novo Nordisk A/S

Completed

Effect of Fiasp® in Type 1 Diabetes Treatment

Diabetes Mellitus, Type 1

Sweden
University of Ljubljana, Faculty of Medicine
Medical University of Graz Department of Pediatrics and Adolescent Medicine... and other collaborators

Completed

Fast Advanced Closed-Loop Therapy (FACT)

Type 1 Diabetes

Austria, Slovenia
Stanford University
Medtronic

Completed

Evaluation of Fiasp® (Fast Acting Insulin Aspart) in 670G Hybrid Closed-Loop Therapy

Diabetes Mellitus, Type 1

United States
McGill University
Juvenile Diabetes Research Foundation

Completed

Pramlintide and Fiasp Closed-Loop With a Simple Meal Announcement

Type 1 Diabetes Mellitus

Canada
Jesús Moreno Fernández
University of Castilla-La Mancha

Completed

Faster Aspart on Insulin-pump Treated T1DM Patients (realFACI)

Type 1 Diabetes

Spain
University Hospital, Antwerp
Universitaire Ziekenhuizen KU Leuven

Completed

The Use of Faster Acting Aspart in Type 1 Diabetes Patients

Type 1 Diabetes | Insulin | Time in Range

Belgium
Mountain Diabetes and Endocrine Center

Unknown

The Efficacy and Safety of Faster Insulin Aspart (Fiasp®) Compared to Conventional Insulin Aspart (NovoLog®) as Correction Bolus (PLATEAU)

Type 1 Diabetes Mellitus

United States
Texas Diabetes & Endocrinology, P.A.

Completed

FIasp® vs. Novolog® in Type 1 Diabetics Using 670G Medtronic Pump

Type 1 Diabetes Mellitus

United States
Eli Lilly and Company

Completed

A Meal Test Study of LY900014 in Participants With Type 1 Diabetes Mellitus

Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Study on How Fiasp® Can Influence Blood Sugar Levels of type1 Diabetic Patients in Their Daily Lives, With the Help of the Freestyle Libre® Device (GoBolus)

Diabetes | Diabetes Mellitus, Type 1 Diabetes

Germany
Aristotle University Of Thessaloniki

Unknown

Fiasp® Versus NovoRapid® in Children With Type 1 Diabetes on MiniMed 640G Pump With Sensor

Type 1 Diabetes

Greece
Arecor Limited

Completed

AT247, NovoRapid® and Fiasp® in Glucose Clamp Study

Diabetes Mellitus, Type 1

Austria
Massachusetts General Hospital

Completed

The Insulin-Only Bionic Pancreas Bridging Study

Type1 Diabetes Mellitus

United States
Novo Nordisk A/S

Completed

Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes (onset® 1)

Diabetes | Diabetes Mellitus, Type 1

United States, Poland, Finland, Belgium, Hungary, United Kingdom, Germany, Canada, Czechia
Novo Nordisk A/S

Completed

Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes (onset® 3)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Mexico, Argentina, Slovenia, Romania
Novo Nordisk A/S

Completed

Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes (onset® 2)

Diabetes Mellitus, Type 2 | Diabetes

United States, Croatia, India, Israel, Russian Federation, Slovakia, Canada, Serbia, United Kingdom, Puerto Rico
Novo Nordisk A/S

Completed

A Trial Investigating the Pharmacokinetic Properties of FIAsp in Japanese Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Japan
Novo Nordisk A/S

Completed

A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Geriatric and Younger Adult Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Institut de Recherches Cliniques de Montreal

Withdrawn

Comparison of the Efficacy of Rapid-acting Aspart and Faster Acting Aspart Within the Context of Single-hormone Closed-loop Strategy at Regulating Postprandial Glucose Levels

Type 1 Diabetes Mellitus
Adocia

Completed

A Trial to Evaluate the Pharmacokinetic and Pharmacodynamic Properties of BioChaperone® Insulin Lispro, Fiasp® and NovoRapid® Delivered by an Insulin Pump

Type1 Diabetes Mellitus

Germany
Novo Nordisk A/S

Completed

A Trial Evaluating Compatibility and Safety of FIAsp and Insulin Aspart With an External Continuous Subcutaneous Insulin Infusion System in Adult Subjects With Type 1 Diabetes (onset® 4)

Diabetes | Diabetes Mellitus, Type 1

United States, Germany
Novo Nordisk A/S

Completed

A Trial Investigating the Pharmacokinetic Properties of FIAsp in Children, Adolescents and Adults With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

A Trial Comparing the Pharmacokinetic Properties of Faster-acting Insulin Aspart (FIAsp) After Different Injection Regions and Routes of Administration in Healthy Subjects

Healthy | Diabetes

Germany
Novo Nordisk A/S

Completed

A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Austria
Novo Nordisk A/S

Completed

A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp When Administered as a Bolus in a Continuous Subcutaneous Infusion Regimen in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Fundacion para la Investigacion Biomedica del Hospital...

Completed

Efficacy and Security of an Endovascular Treatment as First Choice Procedure Compared With a Standard Intravenous Thrombolytic Therapy Treatment for Patients With Acute Ischemic Stroke Within 4.5 Hours After Onset (FUN-TPA)

Acute Ischaemic Stroke

Spain

3

Subscribe